Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Novel Gene Found Related to Cowden Syndrome, Thyroid Cancer

November 6, 2015
By Cancer Network Staff
Article

Researchers identified a novel gene that may predispose individuals to Cowden syndrome, an inherited condition that carries an especially high risk for various epithelial cancers and especially thyroid cancer.

Researchers identified a novel gene that may predispose individuals to Cowden syndrome, an inherited condition that carries an especially high risk for various epithelial cancers and especially thyroid cancer. The gene, which had previously been associated with a rare type of anemia but not with cancer, may help with predictive genetic testing and risk assessment.

Cowden syndrome is difficult to diagnose and recognize; it is characterized by development of multiple hamartomas and an increased lifetime risk of breast, thyroid, endometrial, and other cancers. In previous work, the gene PTEN was identified as a susceptibility gene for Cowden syndrome, with germline mutations occurring in 85% of individuals. Certain mutations increase the risk of thyroid cancer by 45-fold, according to researchers led by Charis Eng, MD, PhD, of the Cleveland Clinic.

In the new study, the researchers sought to identify previously undescribed cancer-predisposing genes in a Cowden syndrome–affected family presenting with different types of related cancers-in particular thyroid cancer, the authors wrote-across four generations. Results were published online in the American Journal of Human Genetics.

They found that all affected family members shared three genes with heterozygous missense variants, and one-in the gene SEC23B-was found to be “the most critical germline variant” in the family.

Next, the researchers looked for the specific SEC23B variation (c.1781T>G [p.Val594Gly]) in a group of 96 other individuals with Cowden syndrome or “Cowden-like” presentation who had thyroid cancer or other cancer types including breast and endometrial carcinomas. They found deleterious SEC23B variants in 3.1% (3 of 96) of the individuals, and papillary thyroid cancer was found in all 3 of those.

The connection was further confirmed using a series of patients with apparently sporadic cancers from the Cancer Genome Atlas. The same germline variants were found in papillary thyroid, breast invasive, and uterine corpus endometrioid carcinomas; the highest frequency was seen in thyroid patients, at 4%.

“Our observations reveal that a subset of Cowden syndrome and Cowden syndrome–like individuals without germline mutations in known genes might be accounted for by germline variants to SEC23B,” the authors concluded. They wrote that additional Cowden syndrome–relevant genes such as this one could “improve molecular diagnosis, especially predictive testing, cancer risk assessment, genetic counseling, and clinical management.”

Recent Videos
Findings may help providers and patients with head and neck cancer consider whether to proceed with radiotherapy modalities, such as proton therapy or IMRT.
Study results appear to affirm anecdotal information from patients with head and neck cancer related to taste changes during and after radiotherapy.
Noah S. Kalman, MD, MBA, describes the rationale for using a test to measure granular details of taste change in patients undergoing radiotherapy for HNC.
The use of a single-port robot may allow for surgically treating more patients with head and neck cancer in a more timely manner, according to Hilary McCrary, MD, MPH.
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.
Related Content
Advertisement

A population-based study led by Cedars-Sinai investigators found that thyroid cancer continues to be overdiagnosed, while the risk of dying from the disease has remained the same.

Aggressive Thyroid Screening/Treatment Not Associated With Higher Survival

Roman Fabbricatore
February 9th 2025
Article

A population-based study led by Cedars-Sinai investigators found that thyroid cancer continues to be overdiagnosed, while the risk of dying from the disease has remained the same.


OncView™ Podcast: Advances in Systemic Therapy of Differentiated Thyroid Cancer

OncView™ Podcast: Advances in Systemic Therapy of Differentiated Thyroid Cancer

Lori Wirth, MD
May 12th 2022
Podcast

In an OncView™ program, Lori Wirth, MD, shared her insights into the current treatment of patients with differentiated thyroid cancer.


Durvalumab Does Not Improve Outcomes Vs Cetuximab in Head and Neck Cancer

Durvalumab Does Not Improve Outcomes Vs Cetuximab in Head and Neck Cancer

Tim Cortese
December 1st 2024
Article

For patients with head and neck squamous cell carcinoma and contraindications to cisplatin, durvalumab yielded worse PFS vs cetuximab.


Younger Thyroid Cancer Survivors at Higher Risk for Late Effects

Younger Thyroid Cancer Survivors at Higher Risk for Late Effects

Brenna Blackburn
February 17th 2017
Podcast

In this interview we discuss a study that found that survivors of thyroid cancer diagnosed with the disease at a young age had an increased risk of late effects from therapy.


While cisplatin was in shortage, clinicians were forced to prescribe costlier alternatives for patients with head and neck cancer.

Cisplatin Shortage Shifted Chemo Utilization to Costlier Therapies for HNC

Roman Fabbricatore
October 16th 2024
Article

While cisplatin was in shortage, clinicians were forced to prescribe costlier alternatives for patients with head and neck cancer.


Data also show an improvement in major pathological response in the perioperative pembrolizumab arm of the KEYNOTE-689 trial.

Perioperative Pembrolizumab Combo Improves EFS in Locally Advanced HNSCC

Russ Conroy
October 8th 2024
Article

Data also show an improvement in major pathological response in the perioperative pembrolizumab arm of the KEYNOTE-689 trial.

Related Content
Advertisement

A population-based study led by Cedars-Sinai investigators found that thyroid cancer continues to be overdiagnosed, while the risk of dying from the disease has remained the same.

Aggressive Thyroid Screening/Treatment Not Associated With Higher Survival

Roman Fabbricatore
February 9th 2025
Article

A population-based study led by Cedars-Sinai investigators found that thyroid cancer continues to be overdiagnosed, while the risk of dying from the disease has remained the same.


OncView™ Podcast: Advances in Systemic Therapy of Differentiated Thyroid Cancer

OncView™ Podcast: Advances in Systemic Therapy of Differentiated Thyroid Cancer

Lori Wirth, MD
May 12th 2022
Podcast

In an OncView™ program, Lori Wirth, MD, shared her insights into the current treatment of patients with differentiated thyroid cancer.


Durvalumab Does Not Improve Outcomes Vs Cetuximab in Head and Neck Cancer

Durvalumab Does Not Improve Outcomes Vs Cetuximab in Head and Neck Cancer

Tim Cortese
December 1st 2024
Article

For patients with head and neck squamous cell carcinoma and contraindications to cisplatin, durvalumab yielded worse PFS vs cetuximab.


Younger Thyroid Cancer Survivors at Higher Risk for Late Effects

Younger Thyroid Cancer Survivors at Higher Risk for Late Effects

Brenna Blackburn
February 17th 2017
Podcast

In this interview we discuss a study that found that survivors of thyroid cancer diagnosed with the disease at a young age had an increased risk of late effects from therapy.


While cisplatin was in shortage, clinicians were forced to prescribe costlier alternatives for patients with head and neck cancer.

Cisplatin Shortage Shifted Chemo Utilization to Costlier Therapies for HNC

Roman Fabbricatore
October 16th 2024
Article

While cisplatin was in shortage, clinicians were forced to prescribe costlier alternatives for patients with head and neck cancer.


Data also show an improvement in major pathological response in the perioperative pembrolizumab arm of the KEYNOTE-689 trial.

Perioperative Pembrolizumab Combo Improves EFS in Locally Advanced HNSCC

Russ Conroy
October 8th 2024
Article

Data also show an improvement in major pathological response in the perioperative pembrolizumab arm of the KEYNOTE-689 trial.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.